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Abstract
Rationale Atypical antipsychotic drugs are characterized by
their affinity for serotonin and dopamine receptors. The
dopaminergic system undergoes developmental changes
during childhood, making it vulnerable to external influences
such as drug administration.
Objective The purpose of this study was to assess the long-
term effects of administering risperidone and quetiapine to
12–24-month-old macaque monkeys on cognitive develop-
ment, a maturational equivalent to 4–8-year-old children.
Methods F o r t ym a l ep i g t a i l e dm a c a q u e sw e r eu s e di nt h es t u d y
(n=20 placebo, n=10 risperidone, n=10 quetiapine). Follow-
ing a 4-month pre-drug period, animals were orally adminis-
tered 2 mg/kg of quetiapine and .025 mg/kg of risperidone
daily for 4 months, then the dosage was doubled for another
4 months. They were followed up for 4 months after cessation
of the drug. Animals were assessed through all phases of the
study on two-object discrimination and learning set.
Results Cognitive development was not negatively affected
whiletheanimalswerebeingadministeredthedrug.However,
the risperidone group had significant decrements in perfor-
mance on the learning set task after cessation of the drug (p=
0.006, ηp
2=0.59). Analysis of errors showed that the
risperidone group had a significant increase in perseverative
responding during the post-drug phase (p=0.002,ηp
2=0.67).
Conclusion As with human studies, neither risperidone nor
quetiapine had a negative impact on cognitive development
during the drug phases. However, the results show that the
risperidone group had behavioral impairment post-drug,
suggesting that the drug may have impacted the develop-
ment of the dopaminergic system.
Keywords Atypical drugs.Risperidone.Quetiapine.
Development.Cognition.Children.Pediatric
Introduction
Atypical antipsychotic drugs, called second-generation
antipsychotics (SGAs), have been shown to be effective in
controlling aggressive and externalizing behaviors, as well
as bipolar disorder in pediatric populations (Bishop and
Pavuluri 2008; Pandina et al. 2007, 2009). All SGAs target
the thalamic–striatal–frontal loop, which has been shown to
be important in several cognitive functions such as reward-
based learning (Schultz 2002), cognitive flexibility (Cools
2006), and working memory (Kellendonk et al. 2006). The
striatal and frontal dopaminergic (DA) systems interact
directly and indirectly through serotonin (5HT) type 2
receptors, which are selectively targeted by SGAs (Schotte
et al. 1996). The 5HT2/D2 affinity ratio of the drug in the
striatium is related to the degree that prefrontal dopamine
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the drug (Kuroki et al. 1999; Meltzer and McGurk 1999).
The 5HT system matures early in development. However,
the DA system has protracted postnatal developmental
trajectories that are divergent for receptor sub-types and
different areas (Lambe et al. 2000; Tarazi and Baldessarini
2000). Within the striatum, neurotransmitter synthesis and
turnover change between early and late childhood (Haycock
et al. 2003). The developmental trajectory of D2 receptors in
the striatum appears to lag behind these changes, peaking in
late childhood then declining into puberty (Andersen and
Teicher 2000; Tarazi and Baldessarini 2000). Within the
frontal cortex, receptor concentrations of D1, D2, and D4
increase from late childhood and into early adolescence, then
concentrations decline to adult levels (Tarazi and Baldessarini
2000; Wahlstrom et al. 2009). These changes, coupled with
the finding that SGAs affect the immature striatal DA system
differently than the mature system (Moran-Gates et al. 2007),
suggest that these drugs could have long-term effects on
cognitive development.
In children, SGAs have been associated with modest
improvements in recognition memory and attention, but
these effects are not large or consistent (Aman et al. 2008;
Gunther et al. 2006; Pandina et al. 2009). One consistent
finding from these studies is that SGAs do not impair
cognition while the child is taking the drug. However, a
major difficulty when judging the cognitive effect in these
studies is that they often include patient groups with large
variations in IQ and do not assess IQ by drug interaction.
These variations in general cognition could be contributing
to the discrepancy in the findings. Additionally, these
studies did not follow up the child after the drug was
discontinued, leaving open the question about how these
drugs interact with the developing DA system.
The main purpose of this study was to assess the effect
of chronic quetiapine or risperidone administration on the
ability to adjust behavior based on feedback. We focused on
this domain because it is well established in nonhuman
primates that DA neurons in the thalamic–striatal–frontal
loop are involved (Tremblay et al. 1998). Additionally,
there are parallel developmental improvements in this
domain through the early juvenile period between humans
(Levinson and Reese 1967; Reese 1989) and nonhuman
primates (Harlow et al. 1960; Mandell and Sackett 2009).
The extended juvenile period in nonhuman primates in
comparison to rats, as well as the established parallels in
cognitive development between nonhuman primates and
humans makes this research especially suited for a monkey
model. These drugs were chosen because both are being
actively prescribed to children as young as 4 years old
(Chang 2008; Kowatch et al. 2005). Additionally, the
receptor affinity profiles make them interesting to compare
in order to disentangle any effects due to 5HT or DA
antagonism. Risperidone has high affinity for 5HT2 and D2
receptors giving it a moderate 5HT2/D2 affinity ratio
(Schotte et al. 1996). Quetiapine, however, has very low
affinity for D2 receptors, giving it one of the highest 5HT2/
D2 affinity ratios in this class of drug (Schotte et al. 1996).
Given the affinity profiles of the drugs, it was expected that
both quetiapine and risperidone would have modest effects
on cognitive development during administration, but only
risperidone would have long-term effects after the drug was
discontinued.
Experimental procedures
Subjects and rearing condition
All procedures were approved by the University of
Washington Institutional Animal Care and Use Committee.
Forty male pigtail macaques (Macaca nemestrina) were
used in the study. All animals were mother-reared in
0.10 ha outdoor corrals at the Tulane National Primate
Research Center, Covington, Louisiana. Between 6 and
7 months of age, juveniles were shipped to the Washington
National Primate Center, Infant Primate Laboratory (IPRL)
in Seattle.
Animals arrived at the IPRL in cohorts of five, all within
30 days of age of each other. They were kept in accordance
with standard husbandry protocols for feeding, cage
cleaning, and health assessments. Although individually
housed with visual and auditory access to other monkeys,
all had 30–45 min of daily playgroup socialization with
their cohort throughout the study.
At 12 months, each cohort was reduced to four animals
in order to balance the drug and placebo monkeys in the
social group. The dropped animal either exhibited abnormal
development or health problems (n=3) or was randomly
chosen (n=7). The remaining four animals in the cohort
were randomly assigned to a drug group so that each cohort
consisted of two placebo animals and two receiving a drug.
This resulted in a sample of 40 animals: 20 received a
placebo, 10 received quetiapine, and 10 received risper-
idone. Animals within a cohort were assigned to the same
drug. All laboratory staff were blind to the experimental
assignment of the animals.
Dosing schedule
Animals were first adapted to the laboratory setting for 4–
6 weeks. During this time, they were trained to drink
butterscotchsyrupoutofasyringe.Afterthisinitialadaptation
period, animals began a 07:00-hour dosing regime that
occurred 7 days a week (Table 1). During the pre-drug
phase that occurred from 9 to 12 months, all animals were
administered the butterscotch placebo at 1 ml/kg of liquid.
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group were given either 2 mg/kg of quetiapine or .025 mg/kg
of risperidone. The drug and placebo were suspended in the
butterscotch solution so that all animalswere receiving1ml/kg
of syrup. The dose was adjusted for each animal once a week
based on his average weight gain the previous week.
Moderate-dose phase: At 17 months, the dosage was doubled
to 4 mg/kg of quetiapine and .05 mg/kg of risperidone. Post-
drug phase: At 21 months, all animals were switched back to
placebo for 2 weeks after which time dosing was discon-
tinued. The moderate dose corresponds to a 1.2-mg/day dose
of risperidone and a 120-mg/day dose of quetiapine for a
30-kg child. Both dose levels are low for children but have
been shown to be clinically effective in pediatric patients
(Bishop and Pavuluri 2008;R o k ee ta l .2009).
Medical and health assessments
Each animal’s weight was assessed daily and growth
measures were taken at the end of each month. Blood
draws were taken without sedation at the end of the first
and third month of each phase. Blood was assayed for
prolactin and thyroxin at the University of Washington
Department of Laboratory Medicine as part of a blood
chemistry panel. Prolactin concentrations and growth for
each group are reported elsewhere (Sackett et al. 2010).
Prolactin results are shown in Table 2. It is important to
note that neither the risperidone nor the quetiapine group
showed abnormal weight gain in comparison to the placebo
animals over the course of the study.
Cognitive testing
Animals began cognitive testing during the pre-drug phase
(Table 1). Cognitive testing was conducted 5 days per week
in a Wisconsin General Testing Apparatus, which has been
described extensively (Mandell and Sackett 2009). Animals
within a cohort were tested at least 3 h but no more than 8 h
after their morning dose. Animals were tested on a battery
of six cognitive tasks (http://depts.washington.edu/iprl/
iprl_testing.html). Each of these tasks was administered at
developmentally appropriate ages; therefore, not all tasks
were administered equally across the drug phases. The tasks
not reported here will be presented in subsequent reports.
In each drug phase, animals were tested on two-object
discrimination. The animal was presented with a black and
a white plastic block, each placed over a well, with one well
containing a small piece of fruit. Either the black or white
block, counterbalanced in the cohort, signaled the location
of the reward on all trials. The location of the reward was
pseudorandomly determined on each trial so that the same
location was not rewarded more than three trials in a row. In
the pre-drug phase, the animal was tested until it was
correct on 90% of the trials in a 24-trial session. In the pre-
drug phase only, the reward association was also reversed.
For the purpose of this study, only the data from the initial
Pre-drug Low-dose Moderate-dose Post-drug
Month 3 Month 1 Month 3 Month 1 Month 3 Month 1
Placebo 10.2 10.1 9.9 10.1 9.7 9.1
(5.9) (6.2) (6.7) (6.3) (7.4) (5.8)
Risperidone 12.5 42.0
a 20.8
a 32.2
a 25.5
a 8.7
a
(4.9) (16.6) (8.8) (14.2) (7.6) (4.3)
Quetiapine 12.5 10.3 6.6 6.4 9.4 9.7
(7.6) (6.3) (2.5) (2.2) (4.5) (4.1)
Table 1 Prolactin
concentrations (ng/ml) over the
study period presented by phase
and month in phase the measure
was taken. Standard deviations
are in parentheses. These data
are published in Sackett et al.
(2010)
aValues significantly different
from the placebo group at each
measurement
Age Pre-drug phase Low-dose phase Moderate-dose phase Post-drug phase
264.2 (17.3) 379.8 (16.6) 491.8 (16.6) 603.9 (16.8)
Two-object discrimination
Placebo 279.2 (20.5) 390.2 (31.7) 499.6 (26.9) 618.9 (38.0)
Risperidone 271.4 (12.9) 395.7 (33.9) 488.8 (14.4) 621.7 (38.8)
Quetiapine 289.6 (27.8) 392.8 (17.7) 525.8 (37.2) 616.8 (17.7)
Learning set
Placebo 367.9 (17.0) 452.6 (24.6) 558.5 (24.7) 621.4 (29.1)
Risperidone 358.5 (12.9) 446.8 (15.9) 535.1 (32.7) 628.2 (37.0)
Quetiapine 371.8 (16.2) 456.1 (31.0) 577.2 (24.2) 624.9 (18.1)
Table 2 Dosing and cognitive
testing schedule with age in
days and standard deviations in
parentheses
Psychopharmacology (2011) 215:345–352 347discrimination was included in the analyses. The reward
association formed during reversal in the pre-drug phase
was maintained through the remaining three phases of the
study. In these phases, the task was administered 1 day a
week for 8 weeks in the two drug phases and for 4 weeks in
the post-drug phase, regardless of performance.
The animal was also tested on learning set formation.
Animals were presented with two unique “junk” objects,
such as old toys and small objects. The objects were
presented using the same procedure as in two-object
discrimination. An object pair was presented for six trials,
and then a new pair was presented. Six object pairs were
presented in each test session. An animal performing this
task is typically 50% correct on the first trial but becomes
better on trials 2 thru 6 as it learns to use the outcome of
trial 1 to guide subsequent behavior. Animals were initially
tested on 240 object pairs that began in the pre-drug phase
and extended into the beginning of the low-dose phase. At
the end of the low-dose phase and in each subsequent
phase, animals were tested on 30 object pairs. In order to
compare performance across all phases, only the last 30
pairs administered in each of the phases were analyzed.
Results
Unless otherwise noted, analyses were conducted with
repeated-measures analysis of variance. The Greenhouse–
Geisser correction was used when assumptions of sphericity
were not met and corrected p values are reported. For each
analysis, drug phase was a within-subjects variable and
drug group was a between-subjects variable. Planned
contrasts were also conducted comparing post-drug perfor-
mance to high- and low-drug phase performance.
Animals improved on two-object discrimination as the
study progressed in terms of overall proportion correct (F
(3, 111)=45.03, p<0.001, ηp
2=0.54). Performance did not
significantly interact with drug group, indicating that
animals in each group were able to learn and maintain the
association comparably across all phases of the study. The
group means during each phase for this task are shown in
Table 3.
Learning set performance showed a different pattern.
There was a significant phase by drug group interaction (F
(6, 108)=2.88, p=0.019, ηp
2=0.14). Planned comparisons
showed that the source of this group difference was
between the moderate- and post-drug phases (F (2, 36)=
6.91, p=0.003, ηp
2=0.28). Performance by the risperidone
group was negatively affected by cessation of the drug.
Their post-drug performance was significantly worse than
their moderate-dose performance (F (1, 9)=12.81, p=.006,
ηp
2=0.59). This performance pattern is in contrast with the
placebo group whose best performance was in the post-drug
phase (low-dose vs. post-drug: p=0.007, ηp
2=0.34;
moderate-dose vs. post-drug: p=0.07, ηp
2=0.17) and the
quetiapine group whose performed at a high level through-
out testing. These relationships are shown in Fig. 1.
In order to determine the source of the performance
decline on learning set, reaction time and response
strategies were analyzed. Reaction times between the
groups were comparable and typical for this task. Animals
were significantly slower on trial 1 than on any other trial
(ηp
2=0.76), this pattern did not significantly interact with
drug group and was maintained into the post-drug phase.
To assess whether the risperidone group engaged in
specific or random errors, performance on the first and
second trials of each object pair was analyzed (Harlow
1949). This grouping resulted in four mutually exclusive
and exhaustive response strategies: (1) correct–correct, (2)
incorrect–correct, (3) incorrect–incorrect, and (4) correct–
incorrect. The most adaptive of these strategies are the first
two, the “win-stay, lose-shift” strategies. The third strategy
is a perseverative strategy and indicates a lack of ability to
use trial 1 information to adjust trial 2 behavior. The fourth
strategy is rare in this species of macaque and indicates
random responding.
Figure 2 shows the utilization rates of the lose–lose and
the lose–win strategies for each group across all four drug
phases. For the optimal lose–win strategy, there was a
nonsignificant interaction between performance on the
moderate- and post-drug phases and drug group. In the
post-drug phase, the risperidone group’s utilization of this
strategy was not significantly lower than the placebo group
but it was significantly lower than the quetiapine group (t
(36)=2.11, p=0.04). For the lose–lose perseverative strat-
egy, there was a significant drug group by phase interaction
(F (6,105)=2.84, p=0.019, ηp
2=0.14). This interaction was
driven by performance differences between the moderate-
and post-drug phases (F (2, 35)=7.56, p=0.002, ηp
2=0.
30). The risperidone group showed a significant increase in
this suboptimal strategy. Their rate of utilization for this
strategy in the post-drug phase was higher than at any time
Table 3 Performance expressed as proportion correct on two-object
discrimination across the four drug phases. Standard deviations are in
parentheses
Pre-drug
phase
Low-dose
phase
Moderate-
dose phase
Post-drug
phase
Placebo 0.72 0.94 0.94 0.93
(0.10) (0.14) (0.08) (0.12)
Risperidone 0.77 0.89 0.93 0.94
(0.12) (0.15) (0.13) (0.12)
Quetiapine 0.68 0.97 0.97 0.99
(0.15) (0.04) (0.02) (0.01)
348 Psychopharmacology (2011) 215:345–352in the study (pre- and post-drug: p=.006, ηp
2=0.59, low-
and post-drug: p=0.07, ηp
2=0.31, moderate- and post-drug:
p=0.002, ηp
2=0.67). Additionally, they utilized this strate-
gy significantly more than the placebo (t (36)=2.38, p=
0.023) or quetiapine group (t (36)=2.75, p=0.009) in the
post-drug phase.
Discussion
As has been shown in human studies assessing the impact
of SGAs on cognitive performance in pediatric populations
(Aman et al. 2008; Gunther et al. 2006; Pandina et al.
2009), neither risperidone nor quetiapine had a negative
impact on cognitive development while the animal was
taking the drug. However, it was clear in this study that
removing risperidone resulted in performance deficits on
learning set a month after drug cessation, which has not
been assessed in the human literature. This deficit was not
due to a lack of attention on the task or to increases in
impulsive responding. Attention on trial 1 is often indexed
via reaction time. A longer reaction time on trial 1 than
trials 2 through 6 suggests that the animal encoded both
stimuli before making a choice. The risperidone group
maintained this reaction time pattern in the post-drug phase,
suggesting that their performance deficit was not due to a
lapse in attention. In animals, impulsive responding can be
shown by faster reaction times. In addition to maintaining
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not have faster reaction times than the other two groups,
indicating that the change in reaction time across the study
was due to developmental changes in global processing
speed, not to impulsive responding. Given that animals in
all three groups were also able to maintain their two-object
discrimination performance at a high level, the deficit seen
in the risperidone animals was not due to a failure to
discriminate either. Rather the performance deficit in the
post-drug phase likely reflects either response inflexibility
or an inability to adjust behavior based on feedback, both of
these explanations are supported by the animals’ persever-
ative behavior on trial 2. Both of these behavioral
explanations suggest an underlying DA disturbance (Cools
et al. 2009; Tremblay et al. 1998).
While a serotonergic disturbance cannot be ruled out, it
is unlikely. Both quetiapine and risperidone impact the
serotonergic system (Tarazi et al. 2002). However, the
quetiapine group did not show a post-drug behavioral
disturbance. It is more likely that the decrement in post-
drug performance by the risperidone group was due to an
effect on the DA system. Quetiapine does not significantly
affect D2 or D4 receptors in vitro (Schotte et al. 1996), and
the animals receiving quetiapine in this study did not show
signs of D2 antagonism as indexed by elevated prolactin
levels (Roke et al. 2009).
Another alternative explanation for these results could be
a disturbance between temporal and frontal functioning.
Disconnecting the fiber tracks between the inferior tempo-
ral and frontal areas has been shown to result in deficits on
learning set performance (Browning et al. 2007). However,
the error types produced by this type of lesion are different
from the ones observed in this study. Disconnection of this
tract produces errors indicative of a general loss in strategy
utilization, whereas in this study, errors were indicative of
behavioral inflexibility. Behavioral inflexibility has been
shown to rely on DA functioning within the thalamic–
striatal–frontal loop (Cools et al. 2009).
While a DA disturbance is likely at the heart of this
behavioral effect, it is unclear where this change is
occurring. Based on the behavioral effects, it is likely that
this problem arises from a DA disturbance in the striatum.
Supersensitivity of D2 receptors in the striatum has been
documented with chronic administration of antipsychotic
drugs. This supersensitivity is often expressed post-drug
and results in psychomotor adverse effects. Supersensi-
tivity of D2 receptors is mainly associated with first-
generation antipsychotic drugs (Samaha et al. 2007;
Seeman et al. 2005), but there is documentation of these
effects with SGAs (Margolese et al. 2002). However, there
was no behavioral or endocrine evidence for supersensi-
tivity in these animals. There was little prolactin adjust-
ment during the moderate-dose phase in the risperidone
group. Additionally, there was no evidence for reaction
time modulation due to the drug being discontinued,
making it unlikely that supersensitivity could be the sole
explanation for the behavioral decrements.
Developmental disturbance of the striatial DA system
can have a cascading effect that is expressed in other
areas. It has been shown that chronic developmental
overexpression of D2 in the striatum results in abnormal
frontal DA functioning with regards to neurotransmitter
turnover, concentration, and D1 receptor density. This
abnormal frontal functioning has been shown to be
related to specific deficits in working memory and
behavioral flexibility, but not to general cognitive
problems (Kellendonk et al. 2006). One of the few studies
to assess the impact of risperidone on developmental
changes in dopamine receptors found that chronic admin-
istration of risperidone in juvenile rats, at a dose level
comparable to the one used here, resulted in increased D2
and D4 concentrations in the hippocampus and medial
prefrontal cortex among other changes (Moran-Gates et al.
2007). Combining these existing studies with our behav-
ioral findings leads to the hypothesis that antagonism of
D2 receptors by risperidone either negatively affected the
developmental downregulation of dopamine receptors in
the striatum or promoted the developmental overexpres-
sion of receptors in the frontal cortex, but this hypothesis
should be tested with more research directly measuring
this system.
While these data show a clear effect of risperidone on
post-drug performance for these young animals, many
questions remain. One question concerns whether the effect
endures over a longer post-drug period. There are no
studies that have assessed whether receptor concentration
changes after SGA drug administration are enduring in
juveniles. In adults, it is reasonable to conclude that the
effects are transient because symptoms return after drug
cessation. With children, it also appears that behavioral
symptoms return after cessation of the drugs, but given that
the drugs are interacting with a developmental process itself
implicated in the behavioral disturbance being treated, it is
an open question as to whether these cognitive and
hypothesized neural changes are enduring.
Another main question that arises from this study is
whether these effects would be present in females. The DA
system has different developmental trajectories for males
and females (Andersen and Teicher 2000) because of a
complex interaction involving the sensitization effects of
sex steroids on DA receptors (Andersen et al. 1997;
Anderson et al. 2005). There have been sex differences
reported in plasma concentrations of SGAs and severity of
adverse effects (Aichhorn et al. 2007). Therefore, it is likely
that the degree to which risperidone and other D2
antagonists affect cognitive development may be different
350 Psychopharmacology (2011) 215:345–352for females and males. Given the findings of this study,
post-drug effects of administering SGAs in young children
should be studied and characterized.
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